Dronabinol and Prograf drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Dronabinol (dronabinol) and Prograf (tacrolimus). Common drug interactions include dehydration among females and acute graft versus host disease in intestine among males.

The phase IV clinical study analyzes what interactions people have when they take Dronabinol and Prograf. It is created by eHealthMe based on reports of 16 people who take the same drugs from the FDA, and is updated regularly.

What is Dronabinol?

Dronabinol has active ingredients of dronabinol. eHealthMe is studying from 5,453 Dronabinol users. Check the latest studies of Dronabinol.

What is Prograf?

Prograf has active ingredients of tacrolimus. It is often used in kidney transplant. eHealthMe is studying from 42,230 Prograf users. Check the latest studies of Prograf.



On Jul, 15, 2026

16 people who take Dronabinol and Prograf together, and have interactions are studied.

Dronabinol and Prograf drug interactions.

What are the common drug interactions of Dronabinol and Prograf, by gender? *:

female:

  1. Dehydration (dryness resulting from the removal of water)
  2. Abdominal tenderness
  3. Catheter site infection (infection at the site of insertion)
  4. Diarrhoea
  5. Graft versus host disease (the donated bone marrow or stem cells view the recipient's body as foreign, and the donated cells/bone marrow attack the body)
  6. Irritable bowel syndrome
  7. Lung disorder (lung disease)
  8. Sepsis (a severe blood infection that can lead to organ failure and death)
  9. Weight decreased

male:

  1. Acute graft versus host disease in intestine (acute complication in intestine following an allogeneic tissue/blood transplant)
  2. Gastrointestinal haemorrhage (bleeding gastrointestinal tract)
  3. Constipation
  4. Contusion (a type of hematoma of tissue in which capillaries)
  5. Death
  6. Encephalopathy (functioning of the brain is affected by some agent or condition)
  7. Fall
  8. Fatigue (feeling of tiredness)
  9. Hospitalisation
  10. Immunosuppressant drug level increased

What are the common drug interactions of Dronabinol and Prograf, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

  1. Acute graft versus host disease in intestine (acute complication in intestine following an allogeneic tissue/blood transplant)
  2. Constipation
  3. Encephalopathy (functioning of the brain is affected by some agent or condition)
  4. Immunosuppressant drug level increased

40-49:

  1. Abdominal pain upper
  2. Oral infection
  3. Rash

50-59:

  1. Dehydration (dryness resulting from the removal of water)
  2. Gastrointestinal haemorrhage (bleeding gastrointestinal tract)
  3. Fall
  4. Fatigue (feeling of tiredness)
  5. Injury
  6. Mental status changes (general changes in brain function, such as confusion, amnesia (memory loss), loss of alertness, loss of orientation)
  7. Nausea (feeling of having an urge to vomit)
  8. Pancytopenia (medical condition in which there is a reduction in the number of red and white blood cells, as well as platelets)
  9. Reticulocyte count increased
  10. Vomiting

60+:

n/a

What are the existing conditions these people have? *

  1. Constipation: 3 people, 18.75%
  2. Pain: 2 people, 12.50%
  3. Deep Venous Thrombosis (blood clot in a major vein that usually develops in the legs and/or pelvis): 2 people, 12.50%
  4. Immunodeficiency Disorders: 2 people, 12.50%
  5. Pvt: 2 people, 12.50%
  6. Rashes (redness): 1 person, 6.25%
  7. Graft Versus Host Disease (the donated bone marrow or stem cells view the recipient's body as foreign, and the donated cells/bone marrow attack the body): 1 person, 6.25%
  8. Asthma: 1 person, 6.25%
  9. Chronic Lymphocytic Leukaemia (cancer in which the bone marrow makes too many lymphocytes (a type of white blood cell)): 1 person, 6.25%
  10. Cystic Fibrosis (disease of the secretary glands): 1 person, 6.25%

* Approximation only. Some reports may have incomplete information.

Do you take Dronabinol and Prograf?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Dronabinol and Prograf:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Dronabinol:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Prograf:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Dronabinol and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Prograf and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on dronabinol and tacrolimus (the active ingredients of Dronabinol and Prograf, respectively), and Dronabinol and Prograf (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: